Brief: Atara Biotherapeutics Provides Regulatory And Business Update On Ebvallo™ (Tabelecleucel)
12/01/2026 13:05
Jan 12 (Reuters) - Atara Biotherapeutics Inc ATRA.O: ATARA BIOTHERAPEUTICS PROVIDES REGULATORY AND BUSINESS UPDATE ON EBVALLO™ (TABELECLEUCEL) ATARA BIOTHERAPEUTICS INC: U.S. FOOD AND DRUG ADMINISTRATION HAS ISSUED A COMPLETE RESPONSE LETTER (CRL) ATARA BIOTHERAPEUTICS INC - FDA ISSUES COMPLETE RESPONSE LETTER FOR EBVALLO BLA ATARA BIOTHERAPEUTICS INC - FDA UNABLE TO APPROVE EBVALLO BLA IN PRESENT FORM Source text: ID:nBw3LZs1ca Further company coverage: ATRA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atara Biotherapeutics
See all newsAtara Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atara Biotherapeutics Q2 revenue falls on deferred revenue recognition
Brief: Atara Biotherapeutics Q2 EPS USD -0.32
Atara Biotherapeutics, Inc. expected to post a loss of 31 cents a share - Earnings Preview
Brief: Atara Biotherapeutics - May Offer Up To $79.27 Million In Common Stock As Of May 12, 2026 - SEC Filing